TY - JOUR
T1 - Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy
AU - Yamashita, Masahiro
AU - Higo, Hisao
AU - Fujii, Nobuharu
AU - Matsumoto, Chiaki
AU - Makimoto, Go
AU - Ninomiya, Kiichiro
AU - Fujii, Masanori
AU - Rai, Kammei
AU - Ichihara, Eiki
AU - Oohashi, Kadoaki
AU - Hotta, Katsuyuki
AU - Tabata, Masahiro
AU - Maeda, Yoshinobu
AU - Miyahara, Nobuaki
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/1
Y1 - 2024/1
N2 - A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
AB - A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
KW - Chimeric antigen receptor-T cell therapy
KW - Coronavirus disease 2019
KW - Multidrug therapy
KW - Organizing pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85202811098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202811098&partnerID=8YFLogxK
U2 - 10.1016/j.rmcr.2024.102104
DO - 10.1016/j.rmcr.2024.102104
M3 - Article
AN - SCOPUS:85202811098
SN - 2213-0071
VL - 51
JO - Respiratory Medicine Case Reports
JF - Respiratory Medicine Case Reports
M1 - 102104
ER -